Moreover, the above discussed clinical trials of DMD all employed dystrophin as the therapeutic protein, which was treated as a “nonconformist” and induced the immune responses that further exacerbated the adverse events. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.